

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10560098
		Filing Date	2006-04-28
		First Named Inventor	Miyazaki et al.
		Art Unit	1643
		Examiner Name	Lynn Anne Bristol
		Attorney Docket Number	14875-0154US1

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5945311		1999-08-31	LINDHOFER et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020142374		2002-10-03	GALLO et al.	
	2	20090117097		2009-05-07	IGAWA et al.	
	3	20090263392		2009-10-22	IGAWA et al.	
	4	20070041978		2007-02-22	HATTORI et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

1	WO2006106903	WO	A1	2006-10-12	IGAWA et al.		<input checked="" type="checkbox"/>
2	WO1996001653	WO	A1	1996-01-25	THORPE et al.		<input type="checkbox"/>
3	EP1510943	EP		2005-03-02	SAITO et al.		<input type="checkbox"/>
4	EP1870459	EP		2007-12-26	IGAWA et al.		<input type="checkbox"/>
5	JP09506001	JP		1997-06-17	LINDHOFER et al.		<input type="checkbox"/>
6	WO9533844	WO		1995-12-14	LINDHOFER et al.		<input type="checkbox"/>
7	WO9803546	WO		1998-01-29	BOONE et al.		<input type="checkbox"/>
8	WO2006106905	WO		2006-10-12	IGAWA et al.		<input type="checkbox"/>
9	WO2005035756	WO	A1	2005-04-21	HATTORI et al.		<input type="checkbox"/>
10	EP1693448	EP		2006-08-23	HATTORI et al.		<input type="checkbox"/>
11	CA2603264	CA		2006-10-19	HATTORI et al.		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

If you wish to add additional Foreign Patent Document citation information please click the Add button				Add
NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T5
	1	BLAZAR, "Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality in Part Via Direct Effects on CD4+ and CD8+ T Cells," J. Immunol., 157:3250-59 (1996)	<input type="checkbox"/>	
	2	*SCHMIDT et al., Human Physiology, Moscow, 2:431-436 (1996), and English translation: SCHMIDT et al., "Hemostasis and Coagulation," Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely Revised Edition, 418-423 [translated by Marguerite A. Biederman-Thorson], Springer-Verlag, 1989	<input checked="" type="checkbox"/>	
	3	SCHMIDT et al., Human Physiology, Moscow, 3:764 (1996), and English translation: SCHMIDT et al., "Enzymes of the pancreatic juice," Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely Revised Edition, 716 [translated by Marguerite A. Biederman-Thorson], Springer-Verlag, 1989	<input checked="" type="checkbox"/>	
	4	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement dated November 18, 2009 in U.S. App. Ser. No. 10/575,905, filed April 16, 2010, 12 pages	<input type="checkbox"/>	
	5	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 23, 2010 in U.S. App. Ser. No. 10/575,905, filed December 22, 2010, 10 pages	<input type="checkbox"/>	
	6	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 23, 2010 in U.S. App. Ser. No. 10/575,193, filed December 22, 2010, 13 pages	<input type="checkbox"/>	
	7	ADAMS et al., "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab," Cancer Immunol. Immunother., 55:717-727 (2006)	<input type="checkbox"/>	
	8	BINZ et al., "Engineering novel binding proteins from nonimmunoglobulin domains," Nat. Biotechnol., 23:1257-68 (2005)	<input type="checkbox"/>	
	9	BRANDEN and TOOZE, "Recognition of Foreign Molecules by the Immune System," Introduction to Protein Structure, 2d Ed., Garland Publishing, pp. 299-323 (1999)	<input type="checkbox"/>	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

10	COMPER and GLASGOW, "Charge selectivity in kidney ultrafiltration," <i>Kidney Int.</i> , 47:1242-51 (1995)	<input type="checkbox"/>
11	COUTO et al., "Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization," <i>Cancer Research</i> , 55:1717-1722 (1995)	<input type="checkbox"/>
12	DEEN et al., "Structural determinants of glomerular permeability," <i>Am. J. Physiol. Renal. Physiol.</i> , 281:F579-F596 (2001)	<input type="checkbox"/>
13	DEL RIO et al., "An Engineered Penicillin Acylase with Altered Surface Charge Is More Stable in Alkaline pH," <i>Ann. NY Acad. Sci.</i> , 799:61-64 (1996)	<input type="checkbox"/>
14	GHETIE and WARD, "FcRn: the MHC class I-related receptor that is more than an IgG transporter," <i>Immunol. Today</i> , 18:592-598 (1997)	<input type="checkbox"/>
15	GHETIE et al., "Increasing the serum persistence of an IgG fragment by random mutagenesis," <i>Nature Biotechnology</i> , 15:637-640 (1997)	<input type="checkbox"/>
16	GHETIE et al., "Multiple roles for the major histocompatibility complex class I- related receptor FcRn," <i>Annu. Rev. Immunol.</i> , 18:739-766 (2000)	<input type="checkbox"/>
17	GOBBURU et al., "Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys," <i>J. Pharmacol. Exp. Ther.</i> , 286:925-930 (1998)	<input type="checkbox"/>
18	GOODE et al., "The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?," <i>Nephrol. Dial. Transplant</i> , 11:1714-16 (1996)	<input type="checkbox"/>
19	GRAVES et al., "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody," <i>Clin. Cancer Res.</i> , 5:899-908 (1999)	<input type="checkbox"/>
20	GUPTA et al., "Affinity chromatography and co-chromatography of bispecific monoclonal antibody immunoconjugates," <i>J. Biochem. Biophys. Methods</i> , 51:203-216 (2002)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

21	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin," J. Immunol., 160:1029-35 (1998)	<input type="checkbox"/>
22	HINTON et al., "An engineered human IgG1 antibody with longer serum half-life," J. Immunol., 176:346-356 (2006)	<input type="checkbox"/>
23	KASHMIRI et al., "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49," Hybridoma, 14:461-473 (1995)	<input type="checkbox"/>
24	KHAWLI et al., "Improved tumor localization and radiomaging with chemically modified monoclonal antibodies," Cancer Biother. Radiopharm., 11:203-215 (1996)	<input type="checkbox"/>
25	KIM et al., "Antibody Engineering for the Development of Therapeutic Antibodies," Mol. Cells, 20:17-29 (2005)	<input type="checkbox"/>
26	KIM et al., "Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-tac monoclonal antibody labeled with ^{99m} Tc," Bioconjugate Chem., 10:447-453 (1999)	<input type="checkbox"/>
27	KIM et al., "Lowering of pI by acylation improves the renal uptake of ^{99m} Tc-labeled anti-Tac dsFv: effect of different acylating reagents," Nucl. Med. Biol., 29:795-801 (2002)	<input type="checkbox"/>
28	KOBAYASHI et al., "The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points," Cancer Res., 59:422-430 (1999)	<input type="checkbox"/>
29	KREUTZ et al., "Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography," J. Chromatogr. B, 714:161-170 (1998)	<input type="checkbox"/>
30	LINDHOFER et al., "Preferential Species-Restricted Heavy/Light Chain Pairing in Rat/Mouse Quadromas," J. Immunol., 155:219-225 (1995)	<input type="checkbox"/>
31	LOBO et al., "Antibody pharmacokinetics and pharmacodynamics," J. Pharm. Sci., 93:2645-68 (2004)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

32	MANZKE et al., "Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography," J. Immunol. Methods, 208:65-73 (1997)	<input type="checkbox"/>
33	MARTIN et al., "Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding," Mol. Cell, 7:867-877 (2001)	<input type="checkbox"/>
34	MARVIN et al., "Recombinant approaches to IgG-like bispecific antibodies," Acta. Pharmacol. Sin., 26:649-658 (2005)	<input type="checkbox"/>
35	ONDA et al., "Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity," Cancer Res., 61:5070-77 (2001)	<input type="checkbox"/>
36	PAVLINKOVA et al., "Charge-modified single chain antibody constructs of monoclonal antibody CC49: Generation, characterization, pharmacokinetics, and biodistribution analysis," Nucl. Med. Biol., 26:27-34 (1999)	<input type="checkbox"/>
37	PAVLOU et al., "The therapeutic antibodies market to 2008," Eur. J. Pharm. Biopharm., 59:389-396 (2005)	<input type="checkbox"/>
38	PODUSLO et al., "Polyamine modification increases the permeability of proteins at the blood – nerve and blood-brain barriers," J. Neurochem., 66:1599-1609 (1996)	<input type="checkbox"/>
39	RAJPAL et al., "A general method for greatly improving the affinity of antibodies by using combinatorial libraries," Proc. Natl. Acad. Sci. USA, 102:8466-71 (2005)	<input type="checkbox"/>
40	REICHERT et al., "Monoclonal antibody successes in the clinic," Nat. Biotechnol., 23:1073-78 (2005)	<input type="checkbox"/>
41	SCHAEFFER et al., "The Rat Glomerular Filtration Barrier Does Not Show Negative Charge Selectivity," Microcirculation, 9:329-342 (2002)	<input type="checkbox"/>
42	SHAUL, "Exploring the charge space of protein-protein association: a proteomic study," Proteins, 60:341-352 (2005)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10560098
Filing Date	2006-04-28
First Named Inventor	Miyazaki et al.
Art Unit	1643
Examiner Name	Lynn Anne Bristol
Attorney Docket Number	14875-0154US1

43	SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R," J. Biol. Chem., 276:6591-6604 (2001) (Epub 11/28/2000)	<input type="checkbox"/>
44	TARDITI et al., "Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies," J. Chromatogr., 599:13-20 (1992)	<input type="checkbox"/>
45	TEN KATE et al., "Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG," Eur. J. Nucl. Med., 17:305-309 (1990)	<input type="checkbox"/>
46	TSURUSHITA et al., "Design of humanized antibodies: From anti-Tac to Zenapax," Methods, 36:69-83 (2005)	<input type="checkbox"/>
47	YAMASAKI et al., "Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors," J. Pharmacol. Exp. Ther., 301:467-477 (2002)	<input type="checkbox"/>
48	YANG et al., "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation," Protein Eng., 16:761-770 (2003)	<input type="checkbox"/>
49	ZUCKIER et al., "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life," Cancer Res., 58:3905-08 (1998)	<input type="checkbox"/>
50	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057058, dated October 21, 2008, 11 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.